• English
  • 日本語
English
Amractionfund
  • About Us
    • Mission
    • Strategy
    • Who we are
    • Investors
    • Testimonials
  • AMR Innovation Challenge
    • The threat of AMR
    • The pipeline problem
    • A sustainable pipeline
    • The role of the fund
  • Our Investments
    • How it works
    • Scope of our investments
    • Stewardship and Access Principles
    • Our Portfolio
  • Resources
  • Contact Us

      Resources

      Filter by category:
      • All
      • Applications
      • Fund Resources
      • In the News
      • News
      • Newsletters
      • Press Releases
      4 Apr, 2022

      AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals

      AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals   Deals mark an important...

      Read More
      7 Feb, 2022

      AMR Action Fund Opens European Office

      AMR Action Fund Opens European Office Swiss office positions Fund to pursue investment opportunities on a truly global scale  

      1 Feb, 2022

      AMR Action Fund Appoints Scientific Advisory Board

      This move brings the Fund, launched one year ago, one step closer to delivering 2 to 4 new antibiotics to...

      21 Jan, 2022

      A timely reality check on silent pandemic of antimicrobial resistance

      A timely reality check on silent pandemic of antimicrobial resistance

      25 Nov, 2021

      We must fix the business model for new antibiotics

      AMR Action Fund CEO Henry Skinner and BIO CEO Dr. Michelle McMurry-Heath co-authored a Fortune op-ed on policy solutions to the...

      18 Nov, 2021

      Pressure grows for market reforms to help tackle ‘silent pandemic’ of AMR

      The Financial Times reported on the challenges of bringing new antibiotics to market and the growing political will to remedy the...

      10 Nov, 2021

      More Investment Sorely Needed to Combat Antimicrobial Resistance

      MedPage today reported on the struggles that some biotechs face as they develop antibiotics. The article featured news from the...

      12 Oct, 2021

      Antibiotic resistance in the patient with cancer

      The current focus on the coronavirus disease 2019 (COVID-19) pandemic means a lack of attention to other health challenges, such as antimicrobial resis- tance.

      12 Oct, 2021

      Legislation Aims to Jump Start Antibiotic Development

      Before joining the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Duffy served as executive vice president and chief scientific officer at Melinta Therapeutics, a developer of new antibiotics.

      Show More
      Amractionfund
      © 2022 AMR Action Fund All rights reserved. |
      • Japan Disclaimer
      • Privacy Policy